Briacell Therapeutics Corp (BCTX) Stock Analysis

Briacell Therapeutics Corp (BCTX) is a publicly traded company in the HEALTHCARE sector. It trades at $3.27, carries a market capitalization of $26.39M. This page summarizes the public market data, fundamentals, and frequently asked questions for BCTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Briacell Therapeutics Corp currently has a Bullish sentiment score of 0.64.

About Briacell Therapeutics Corp

Briacell Therapeutics Corp. is a clinical-stage biotechnology firm based in West Vancouver, Canada, specializing in personalized immunotherapy solutions for cancer, particularly breast cancer. The company is developing its proprietary platform, focusing on leveraging the immune system to effectively target tumors. Its lead candidate, Bria-imiRNA-132, aims to enhance the immune response against cancer cells, showcasing significant potential within the oncology market. With a strong emphasis on...

GNG Research Analysis

GNG Research scores Briacell Therapeutics Corp (BCTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BCTX.

Frequently Asked Questions

Does BCTX pay dividends?

Briacell Therapeutics Corp (BCTX) does not currently pay a regular dividend.

What is BCTX's market cap?

Briacell Therapeutics Corp (BCTX) has a market capitalization of $26.39M with a current stock price of $3.27.